A
The startup develops immunotherapy technologies that utilize active therapeutic molecules to target mucosal cancers. By identifying and demonstrating the efficacy of biologically derived compounds, the company enhances treatment options for healthcare professionals, improving patient outcomes in oncology.
Updated 20 months ago
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops immunotherapy technologies that utilize active therapeutic molecules to target mucosal cancers. By identifying and demonstrating the efficacy of biologically derived compounds, the company enhances treatment options for healthcare professionals, improving patient outcomes in oncology.